CRISPR Therapeutics AG
CRSP- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001674416
In the last 90 days, CRISPR Therapeutics AG insiders filed 0 open-market purchases and 2 sales; 525 institutions reported holding it in 13F filings for Q2 2026, worth $4.16B in total; ARK Invest is the only superinvestor holding it.
Q2 2024 vs. Q1 2024
How the institutions holding CRISPR Therapeutics AG changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 483 | 7 | 450 | −26 |
| Shares | 59.1M | 734.3K | 59.6M | +1.20M (+2.1%) |
| Value | $4.10B | $50.1M | $3.22B | −$829.3M (−20.5%) |
7 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (49)
Institutions that held CRISPR Therapeutics AG at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (75)
Institutions that held CRISPR Therapeutics AG at the end of Q1 2024 and filed for Q2 2024 without it.
Not filed for Q2 2024 yet (7)
Institutions that held CRISPR Therapeutics AG at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 719,309 | $49.0M |
| Merlin Capital LLC | 8,879 | $605.2K |
| Derbend Asset Management | 3,673 | $250.4K |
| Cambridge Trust Co | 1,500 | $102.2K |
| Cutler Group LP | 700 | $47.0K |
| Retirement Group, LLC | 200 | $13.6K |
| Pflug Koory, LLC | 84 | $5.72K |